SELLAS Life Sciences Group Inc (SLS)
1.33
-0.02
(-1.48%)
USD |
NASDAQ |
May 03, 16:00
1.315
-0.02
(-1.13%)
After-Hours: 20:00
SELLAS Life Sciences Group SG&A Expense (Quarterly): 3.08M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 3.08M |
September 30, 2023 | 3.548M |
June 30, 2023 | 3.127M |
March 31, 2023 | 4.107M |
December 31, 2022 | 3.60M |
September 30, 2022 | 2.864M |
June 30, 2022 | 3.094M |
March 31, 2022 | 3.024M |
December 31, 2021 | 2.526M |
September 30, 2021 | 2.436M |
June 30, 2021 | 2.797M |
March 31, 2021 | 3.561M |
December 31, 2020 | 3.288M |
September 30, 2020 | 2.125M |
June 30, 2020 | 1.987M |
March 31, 2020 | 2.20M |
December 31, 2019 | 2.40M |
September 30, 2019 | 2.385M |
June 30, 2019 | 2.638M |
March 31, 2019 | 2.50M |
December 31, 2018 | 2.642M |
September 30, 2018 | 1.341M |
June 30, 2018 | 4.909M |
March 31, 2018 | 3.88M |
December 31, 2017 | 5.985M |
Date | Value |
---|---|
September 30, 2017 | 3.511M |
June 30, 2017 | 3.841M |
March 31, 2017 | 2.287M |
December 31, 2016 | -4.897M |
September 30, 2016 | 2.848M |
June 30, 2016 | 3.117M |
March 31, 2016 | 3.525M |
December 31, 2015 | 2.74M |
September 30, 2015 | 2.895M |
June 30, 2015 | 1.886M |
March 31, 2015 | 3.087M |
December 31, 2014 | 3.482M |
September 30, 2014 | 3.542M |
June 30, 2014 | 9.60M |
March 31, 2014 | 6.83M |
December 31, 2013 | -0.304M |
September 30, 2013 | 4.129M |
June 30, 2013 | 2.71M |
March 31, 2013 | 1.53M |
December 31, 2012 | 1.517M |
September 30, 2012 | 1.359M |
June 30, 2012 | 1.963M |
March 31, 2012 | 1.746M |
December 31, 2011 | 1.499M |
September 30, 2011 | 2.068M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.987M
Minimum
Jun 2020
4.107M
Maximum
Mar 2023
2.884M
Average
2.864M
Median
Sep 2022
SG&A Expense (Quarterly) Benchmarks
Geron Corp | 27.06M |
Immuneering Corp | 4.385M |
Protagonist Therapeutics Inc | 8.052M |
Akebia Therapeutics Inc | 25.44M |
Moderna Inc | 274.00M |